secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103527
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint Q2 net loss $59.4M; completes Phase 3 enrollment for DURAVYU in wet AMD
--------------------------------------------------------------------------------

- Net revenue $5.3M, down from $9.5M YoY; net loss $59.4M ($0.85/share) vs. $30.8M ($0.58/share) in Q2 2024.
- Total operating expenses $67.6M, up from $44.0M, driven by DURAVYU Phase 3 trial costs.
- Cash, equivalents and marketable securities $256M as of June 30, 2025; cash runway into 2027.
- Completed enrollment in both Phase 3 wet AMD trials (LUGANO and LUCIA) with over 800 patients; topline LUGANO data mid-2026.
- Initiated DURAVYU registration batches at Northbridge, MA commercial manufacturing facility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025103527/0000950170-25-103527-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000095017025103527/eypt-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103527

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer